Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Protection against persistence of hepatitis C.

Mehta SH, Cox A, Hoover DR, Wang XH, Mao Q, Ray S, Strathdee SA, Vlahov D, Thomas DL.

Lancet. 2002 Apr 27;359(9316):1478-83.

PMID:
11988247
2.

Hepatitis C virus reinfection in injection drug users.

Grebely J, Conway B, Raffa JD, Lai C, Krajden M, Tyndall MW.

Hepatology. 2006 Nov;44(5):1139-45.

PMID:
17058216
3.

Effect of coexisting HIV-1 infection on the diagnosis and evaluation of hepatitis C virus.

Bonacini M, Lin HJ, Hollinger FB.

J Acquir Immune Defic Syndr. 2001 Apr 1;26(4):340-4.

PMID:
11317075
4.

Impaired hepatitis C virus-specific T cell responses and recurrent hepatitis C virus in HIV coinfection.

Kim AY, Schulze zur Wiesch J, Kuntzen T, Timm J, Kaufmann DE, Duncan JE, Jones AM, Wurcel AG, Davis BT, Gandhi RT, Robbins GK, Allen TM, Chung RT, Lauer GM, Walker BD.

PLoS Med. 2006 Dec;3(12):e492.

5.

Viral clearance or persistence after acute hepatitis C infection: interim results from a prospective study.

Guobuzaite A, Chokshi S, Balciūniene L, Voinic A, Stikleryte A, Zagminas K, Ambrozaitis A, Naoumov N.

Medicina (Kaunas). 2008;44(7):510-20.

6.

High incidence of hepatitis C virus reinfection within a cohort of injecting drug users.

Micallef JM, Macdonald V, Jauncey M, Amin J, Rawlinson W, van Beek I, Kaldor JM, White PA, Dore GJ.

J Viral Hepat. 2007 Jun;14(6):413-8.

PMID:
17501762
7.

Hepatitis C virus viremia in HIV-infected individuals with negative HCV antibody tests.

George SL, Gebhardt J, Klinzman D, Foster MB, Patrick KD, Schmidt WN, Alden B, Pfaller MA, Stapleton JT.

J Acquir Immune Defic Syndr. 2002 Oct 1;31(2):154-62.

PMID:
12394793
8.

Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.

Antonucci G, Girardi E, Cozzi-Lepri A, Capobianchi MR, De Luca A, Puoti M, Petrelli E, Carnevale G, Rizzardini G, Grossi PA, Viganò P, Moioli MC, Carletti F, Solmone M, Ippolito G, Monforte AD; HepaI.Co.N.A. Study Group; Italian Cohort Naive for Antiretrovirals Study Group.

Clin Infect Dis. 2005 Jun 15;40(12):e101-9. Epub 2005 May 5.

PMID:
15909251
9.

High rate of hepatitis C virus (HCV) recurrence in HIV-infected individuals with spontaneous HCV RNA clearance.

Peters L, Mocroft A, Soriano V, Rockstroh JK, Kirkby N, Reiss P, Katlama C, Zakharova N, Flisiak R, Lundgren JD; EuroSIDA in EuroCoord.

HIV Med. 2014 Nov;15(10):615-20. doi: 10.1111/hiv.12160. Epub 2014 May 11.

10.

Human immunodeficiency virus type 1-hepatitis C virus coinfection: intraindividual comparison of cellular immune responses against two persistent viruses.

Lauer GM, Nguyen TN, Day CL, Robbins GK, Flynn T, McGowan K, Rosenberg ES, Lucas M, Klenerman P, Chung RT, Walker BD.

J Virol. 2002 Mar;76(6):2817-26.

11.

CD4+ T-Cell-Dependent Reduction in Hepatitis C Virus-Specific Neutralizing Antibody Responses After Coinfection With Human Immunodeficiency Virus.

Bailey JR, Dowd KA, Snider AE, Osburn WO, Mehta SH, Kirk GD, Thomas DL, Ray SC.

J Infect Dis. 2015 Sep 15;212(6):914-23. doi: 10.1093/infdis/jiv139. Epub 2015 Mar 9.

12.

Hepatitis B virus and hepatitis C virus infection among HIV-1-infected injection drug users in Dali, China: prevalence and infection status in a cross-sectional study.

Dong Y, Qiu C, Xia X, Wang J, Zhang H, Zhang X, Xu J.

Arch Virol. 2015 Apr;160(4):929-36. doi: 10.1007/s00705-014-2311-0. Epub 2015 Jan 24.

PMID:
25616842
13.

Relationship of hepatitis C viremia to HIV state and to infection by specific hepatitis C genotypes.

Pérez-Gracia T, Galán F, Fernández-Gutiérrez C, Girón JA, Rodríguez-Iglesias M.

Liver. 1999 Aug;19(4):288-93.

PMID:
10459626
14.
16.

Impact of early-untreated HIV infection on chronic hepatitis C in intravenous drug users: a case-control study.

Serfaty L, Costagliola D, Wendum D, Picard O, Meyohas MC, Girard PM, Lebas J, Delamare C, Poupon R, Housset C.

AIDS. 2001 Oct 19;15(15):2011-6.

PMID:
11600830
17.

HIV and HCV co-infection: situation at six French university hospitals in the year 2000.

Buffet-Janvresse C, Peigue-Lafeuille H, Benichou J, Vabret A, Branger M, Trimoulet P, Goria O, Laurichesse H, Abbed A, Verdon R, Bouvet E, Lafon ME, Dussaix E, Cormerais L, Dupon M, Henquell C, Josse A, Lagoutte P, Lariven S, LeGac S, Riachi G, Verdon R, Vittecoq D; HIV-HCV Cohort Study Group.

J Med Virol. 2003 Jan;69(1):7-17.

PMID:
12436472
18.

Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects.

De Luca A, Bugarini R, Lepri AC, Puoti M, Girardi E, Antinori A, Poggio A, Pagano G, Tositti G, Cadeo G, Macor A, Toti M, D'Arminio Monforte A; Italian Cohort Naive Antiretrovirals Study Group.

Arch Intern Med. 2002 Oct 14;162(18):2125-32.

PMID:
12374521
19.

Hepatitis C virus-specific cellular immune responses in sustained virological responders with viral persistence in peripheral blood mononuclear cells.

Roque-Cuéllar MC, Sánchez B, García-Lozano JR, Praena-Fernández JM, Márquez-Galán JL, Núñez-Roldán A, Aguilar-Reina J.

Liver Int. 2014 Jul;34(6):e80-8. doi: 10.1111/liv.12320. Epub 2013 Oct 16.

PMID:
24127783
20.

Secondary persistent infection with hepatitis C virus: a challenge for adaptive immunity.

Grant M.

Lancet. 2002 Apr 27;359(9316):1452. No abstract available.

PMID:
11988241

Supplemental Content

Support Center